|Bid||225.09 x 900|
|Ask||226.95 x 900|
|Day's Range||227.54 - 242.51|
|52 Week Range||6.77 - 331.68|
|Beta (5Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||253.75|
Novavax (NVAX) is hoping its trial data from the United Kingdom and South Africa can be aggregated and used to apply for an emergency use authorization (EAU) in the U.S. to help expedite the rollout of its COVID-19 vaccine.
Tiger Tyagarajan, Genpact CEO & President, joins Yahoo Finance’s Alexis Christoforous to discuss vaccine outlook amid the pandemic.
Johnson & Johnson’s single-shot coronavirus vaccine wins FDA approval. Yahoo FInance’s Anjalee Khemlani breaks down the details.